Treatment strategy to eradicate Helicobacter pylori infection: Impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 16, 2007, Pages 2701-2717

  Sugimoto, Mitsushige ^a   Furuta, Takahisa ^a   Shirai, Naohito ^a   Kodaira, Chise ^a   Nishino, Masafumi ^a   Yamade, Mihoko ^a   Ikuma, Mutsuhiro ^a   Watanabe, Hiroshi ^a   Ohashi, Kyoichi ^a   Hishida, Akira ^a   Ishizaki, Takashi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytochrome P45O 2C19; Eradication therapy; H2RA; Helicobacter pylori; MDR1; PPI; Pro inflammatory cytokine

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BENATOPRAZOLE; BISMUTH CITRATE; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOKINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TETRACYCLINE; ABCB1 PROTEIN, HUMAN; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; GLYCOPROTEIN P; MIXED FUNCTION OXIDASE; PROTON PUMP; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; REVIEW; STOMACH ACID SECRETION; STOMACH PH; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; GENETICS; METABOLISM; PHARMACOGENETICS; STOMACH ACID;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOKINES; DRUG RESISTANCE, BACTERIAL; GASTRIC ACID; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTON PUMPS;

EID: 36049033608     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.16.2701     Document Type: Review

References (99)

1. UEMURA N, OKAMOTO S, YAMAMOTO S et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. (2001) 345:784-789.
2. WONG BC, LAM SK, WONG WM et al.: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA (2004) 291:187-194.
3. HOPKINS RJ, GIRARDI LS, TURNEY EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gartroenterology (1996) 110:1244-1252.
4. UEMURA N, MUKAI T, OKAMOTO S et al.: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. (1997) 6:639-642.
5. WOTHERSPOON AC, DOGLIONI C, DE BONI M, SPENCER J, ISAACSON PG: Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet (1994) 343:1503.
6. SUGIMOTO M, KAJIMURA M, SHIRAI N et al.: Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Intern. Med. (2006) 45:405-409.
7. GASBARRINI A, FRANCESCHI F, TARTAGLIONE R, LANDOLFI R, POLA P, GASBARRINI G: Regression of autoinimune thrombocytopenia. after eradication of Helicobacter pylori. Lancet (1998) 352:878.
8. TEBBE B, GEILEN CC, SCHULZKE JD, BOJARSKI C, RADENHAUSEN M, ORFANOS CE: Helicobacter pylori infection and chronic urticaria. J. Am. Acad. Dermatol. (1996) 34:685-686.
9. ANNIBALE B, MARIGNANI M, MONARCA B et al.: Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastrids. Ann. Intern. Med. (1999) 131:668-672.
10. ASAKA M, SUGIYAMA T, KATO M et al.: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter (2001) 6:254-261.
11. MURAKAMI K, SATO R, OKIMOTO T et al.: Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. (2002) 16:1933-1938.
12. FURUTA T, SHIRAI N, TAKASHIMA M et al.: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. (2001) 69:158-168.
13. CAMMAROTA G, CIANCI R, CANNIZZARO O et al.: Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2000) 14:1339-1343.
14. SHARARA AI, CHAAR HF, AOUN E, ABDUL-BAKI H, ARAJ GF, KANJ SS: Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter (2006) 11:231-236.
15. MURAKAMI K, SATO R, OKIMOTO T et al.: Efficacy of triple therapy comprising rabeprazole, amoxiciflin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. (2003) 17:119-123.
16. KAWAKAMI E, MACHADO RS, OGATA SK et al.: Furazolidone-based triple therapy for H. pylori gastritis in children. World J. Gastroenterol. (2006) 12:5544-5549.
17. ISOMOTO H, INOUE K, FURUSU H et al.: High-dose rabeprazole-amoxicillin versus rabeprizole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 18:101-107.
18. MEGRAUD F: Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology (1998) 115:1278-1282.
19. SAAD RJ, SCHOENFELD P, KIM HM, CHEY WD: Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a mem-analysis. Am. J. Gastmenterol. (2006) 101:488-496.
20. GISBERT JP, MORENA F: Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. (2006) 23:35-44.
21. GRAYSON ML, ELIOPOULOS GM, FERRARO MJ, MOELLERING RC Jr: Effect of varying PH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. (1989) 8:888-889.
22. HUNT RH: PH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am. J. Gastroenterol. (1993) 88:481-483.
23. PETERSON WL: The role of antisecretory drugs in the treatment of Helicobarter pylori infection. Aliment. Pharmacol. Ther. (1997) 11(Suppl. 1):21-25.
24. LABENZ J, STOLTE M, BLUM AL et al.: Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut (1995) 37:39-43.
25. SUGIMOTO M, FURUTA T, SHIRAI N et al.: Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter (2007) 12 (4):317-323.
26. HIXSON LJ, KELLEY CL, JONES WN, TUOHY CD: Current trends in the pharmacotherapy for peptic ulcer disease. Arch. Intern. Med. (1992) 152:726-732.
27. ISHIZAKI T, HORAI Y: Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. (1999) 13(Suppl. 3):27-36.
28. CHANG M, DAHL ML, TYBRING G, GOTHARSON E, BERTILSSON L: Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 5:358-363.
29. KUBOTA T, CHIBA K, ISHIZAKI T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. (1996) 60:661-666.
30. SIM SC, RISINGER C, DAHL ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump, inhibitors and antidepressants. Clin. Pharmacol. Ther. (2006) 79:103-113.
31. ISHIZAKI T, SOHN DR, KOBAYASHI K et al.: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug Monit. (1994) 16:214-215.
32. DE MORAIS SM, GOLDSTEIN JA, XIE HG et al.: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin. Pharmacol. Ther. (1995) 58:404-411.
33. SHIRAI N, FURUTAT, MORIYAMA Y et al.: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric PH. Aliment. Pharmacol. Ther. (2001) 15:1929-1937.
34. SHIRAI N, FURUTA T, XIAO F et al.: Comparison of lansoprazole and Famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment. Pharmacol, Ther. (2002) 16:837-846.
35. SUGIMOTO M, FURUTA T, SHIRAI N et al.: Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. (2004) 76:290-301.
36. FURUTA T, OHASHI K, KOSUGE K et al.: CYP2C19 genotype status and effect of omeprazole on intragastric PH in humans. Clin. Pharmacol. Ther. (1999) 65:552-561.
37. FURUTA T, SHIRAI N, XIAO F, ORASHI K, ISHIZAKI T: Effect of high-dose lansoprazole on intragastric PH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. (2001) 70:484-492.
38. KLOTZ U, SCHWAB M, TREIBER G: CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol. (2004) 95:2-8.
39. YASUDA S, HORAI Y, TOMONO Y et al.: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin. Pharmacol. Ther. (1995) 58:143-154.
40. ADACHI K, KATSUBE T, KAWAMURA A et al.: CYP2C19 genotype status and intragastric PH during dosing with lansoprazole or rabeprazole. Aliment. Pharmcol. Ther. (2000) 14:1259-1266.
41. HORAI Y, KIMURA M, FURUIE H et al.: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol. Ther. (2001) 15:793-803.
42. IEIRI I, KISHIMOTO Y, OKOCHI H et al.: Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur. J. Clin. Pharmacol. (2001) 57:485-492.
43. SHIMATANI T, INOUE M, KUROIWA T, HORIKAWA Y: Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment. Pharmacol. Ther. (2004) 19:113-122.
44. SUGIMOTO M, FURUTA T, SHIRAI N et al.: Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin. Pharmacol Ther. (2005) 77:302-311.
45. SAPONE A, VAIRA D, TRESPIDI S et al.: The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am. J. Gastroenteral (2003) 98:1010-1015.
46. AOYAMA N, TANIGAWARA Y, KITA T et al.: Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cycochrome P450 2C19 poor metabolizers. J. Gastraenterol. (1999) 34(Suppl. 11):80-83.
47. SCHWAB M, SCHAEFFELER E, KLOTZ U, TREIBER G: CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin. Pharmacol. Ther. (2004) 76:201-209.
48. KURZAWSKI M, GAWRONSKA-SZKLARZ B, WRZESNIEWSKA J, SIUDA A, STARZYNSKA T, DROZDZIK M: Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur. J. Clin. Pharmacol. (2006) 62:877-880.
49. PADOL S, YUAN Y, THABANE M, PADOL IT, HUNT RH: The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. (2006) 101:1467-1475.
50. BOYANOVA L, MENTIS A, GUBINA M et al.: The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin. Microbiol. Infect. (2002) 8:388-396.
51. FURUTAT, SHIRAI N, XIAO F et al.: High-dose rabeprazole/ amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology (2003) 50:2274-2278.
52. FURUTA T, SHIRAI N, TAKASHIMA M et al: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmatogenetics (2001) 11:341-348.
53. FURUTA T, SHIRAI N, KODAIRA M et al.: Pharmacogenomics-based tailored versus standard therapeutic regimens for eradication of H. pylori. Clin. Pharmacol. Ther. (2007) 81:521-528.
54. CASCORBI I, GERLOFF T, JOHNE A et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 69:169-174.
55. PAULI-MAGNUS C, REKERSBRINK S, KLOTZ U, FROMM MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. (2001) 364:551-557.
56. HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:3473-3478.
57. GAWRONSKA-SZKLARZ B, WRZESNIEWSKA J, STARZYNSKA T et al.: Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur. J. Clin. Pharmacol. (2005) 61:0375-379.
58. NAKAMURA T, SAKAEDA T, HORINOUCHI M et al.: Effect of the mutation (C3435T) at exon 26 of the MDRI gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. (2002) 71:297-303.
59. WOLFE MM, NOMPLEGGI DJ: Cytokine inhibition of gastric acid secretion - a little goes a long way. Gastroenterology (1992) 102:2177-2178.
60. KONDO S, SHINOMURA Y, KANAYAMA S et al.: Interleukin-1β inhibits gastric histamine secretion and synthesis in the rat. Am. J. Physiol. (1994) 267:G966-G971.
61. TAKASHIMA M, FURUTA T, HANAI H, SUGIMURA H, KANEKO E: Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. Gut (2001) 48:765-773.
62. WANG M, FURUTA T, TAKASHIMA M et al.: Relation between interleukin-10 messenger RNA in gastric fundic mucosa. and gastric juice pH in patients infected with Helicobacter pylori. J. Gastroenterol. (1999) 34(Suppl. 11):10-17.
63. FURUTA T, EL-OMAR EM, XIA0 F et al.: Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology (2002) 123:92-105.
64. FURUTA T, SHIRAI N, XIAO, F et al.: Polymorphism of interleukin-1β affects the eradication rates of Helicobacter pylori by triple therapy. Clin. Gastroenterol. Hepatol. (2004) 2 :22-30.
65. SUGIMOTO M, FURUTA T, SHIRAI N et al.: Different effects of polymorphisms of TNF-α and interleukin-1β on development of peptic ulcer and gastric cancer. J. Gastroenterol. Hepatol. (2007) 22:51-59.
66. SUGIMOTO M, FURUTA T, SHIRAI N et al.: Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese. J. Gastroenterol. Hepatol. (2007) 22:1443-1449.
67. EL-OMAR EM, CARRINGTON M, CHOW WH et al.: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 404:398-402.
68. HWANG IR, KODAMAT, KIKUCHI S et al.: Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1β production in Helicobacter pylori infection. Gastroenterology (2002) 123:1793-1803.
69. SUGIMOTO M, FURUTA T, SHIRAI N, IKUMA M, HISHIDA A, ISHIZAKI T: Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin. Pharmacol. Ther. (2006) 80:41-50.
70. ISHIDA Y, GOTO Y, KONDO T et al.: Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-α. Int. J. Med. Sci. (2006) 3:135-140.
71. BEALES IL, CALAM J: Interleukin 1β and TNF-α inhibit acid secretion in cultured rabbit parietall cells by multiple pathways. Gut (1998) 42:227-234.
72. HATLEBAKK JG: Review article: gastric acidity - comparison of esomeprazole with other proton pump inhibitors. Aliment. Pharmacol Ther. (2003) 17(Suppl. 1): 10- 15; discussion 16-17.
73. STEDMAN CA, BARCLAY ML: Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment. Pharmacol. Ther. (2000) 14:963-978.
74. HUNT RH, ARMSTRONG D, JAMES C et al.: Effect on intragastric PH of a PPI with a prolonged plasma half-life. comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am. J. Gastroenterol. (2005) 100:1949-1956.
75. GLADZIWA U, KOLTZ U: Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin. Pharmacokinet. (1994) 27:393-408.
76. SUGIMOTO M, FURUTA T, SHIRAI N, IKUMA M, HISHIDA A, ISHIZAKI T: Initial 48-h acid inhibition by intravenous infusion of omeprazole, Famotidine, or both in relation to cyrochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. (2006) 80:539-548.
77. ABE Y, INAMORI M, TOGAWA J et al.: The comparative effects of single intravenous doses of omcprazole and famotidine on intragastric PH. J. Gastroenterol. (2004) 39:21-25.
78. PEGHINI PL, KATZ PO, CASTELL DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology (1998) 115:1335-1339.
79. KATSUBE T, ADACHI K, KAWAMURA A et al.: Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment. Pharmacol. Ther. (2000) 14:1049-1056.
80. GISBERT JP, KHORRAMI S, CALVET X, PAJARES JM: Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. (2004) 16:89-99.
81. GISBERT JP, PAJARES JM: Esomeprazole-based therapy in Heicobacter pylori eradication: a meta-analysis. Dig. Liver Dis. (2004) 36:253-259.
82. MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut (2007) 56:772-781.
83. HSU PI, LAI KH, LIN CK et al.: A prospective randomized trial of esomeprazole-versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am. J. Gastroenterol (2005) 100:2387-2392.
84. KOSITCHAIWAT C, OVARTLARNPORN B, KACHINTORN U, ATISOOK K. Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 18:1017-1021.
85. GISBERT JP, KHORRAMI S, CALVET X, GABRIEL R, CARBALLO F, PAJARES JM: Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists - their efficacy with antibiotics in Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2003) 18:757-766.
86. OKUDAIRA K, FURUTA T, SHIRAI N, SUGIMOTO M, MIURA S: Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment. Pharmacol. Ther. (2005) 21:491-497.
87. ADAMEK RJ, SUERBAUM S, PEAFFENBACH B, OPFERKUCH W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am. J. Gastroenterol. (1998) 93:386-389.
88. NARIKAWA S: Distribution of metronidazole susceptibility factors in obligate anaerobes. J. Antimicrob. Chemother. (1986) 18:565-574.
89. MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 consensus report. Aliment. Pharmacol. Ther. (2002) 16:167-180.
90. SHIRAI N, SUGIMOTO M, KODAIRA C et al.: Dual therapy with high doses of rabeprazolle and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as the rescue regimen for Helicobacter pylori infection after triple therapy. Eur. J. Clin. Pharmacol. (2007) 63(8):743-749.
91. WATANABE Y, AOYAMA N, SHIRASAKA D et al.: Levofloxacin based triple therapy as a second-line treatment after fiflure of Helicobacter pylori eradication with standard triple therapy. Dig. Liver Dis. (2003) 35:711-715.
92. GATTA L, ZULLO A, PERNA F et al.: A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment. Pharmacol. Ther. (2005) 22:45-49.
93. MIYACHI H, MIKI I, AOYAMA N et al.: Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter (2006) 11:243-249.
94. MATSUMOTO Y, MIKI I, AOYAMA N et al.: Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig. Liver Dis. (2005) 37:821-825.
95. BAYERDORFFER. E, MIEHLKE S, MANNES GA et al.: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology (1995) 108:1412-1417.
96. MIEHLKE S, KIRSCH C, SCHNEIDER-BRACHERT W et al.: A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter (2003) 8:310-319.
97. ATHAMNA A, ATHAMNA M, MEDLEJ B, BAST DJ, RUBINSTEIN E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/datfopristin and rifampicin on Bacillus anthracis. J. Antimicrob. Chemother. (2004) 53:609-615.
98. FURUTA T, SHIRAI N, OHASHI K, ISHIZAKI T. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find. Exp. Clin. Pharmacol. (2003) 25:131-143.
99. FURUTA T, SHIRAI N, SUGIMOTO M, OHASHI K, ISHIZAKI T: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics (2004) 5:181-202.